A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

PURPOSE. Nintedanib enhances the activity of chemotherapy in metastatic NSCLC. In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. EXPERIMENTAL DESIGN: Eligible patients had stage IB (≥4 cm)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Cascone, Tina, Sepesi, Boris, Lin, Heather Y., Kalhor, Neda, Parra, Edwin R., Jiang, Mei, Godoy, Myrna C. B., Zhang, Jianjun, Fossella, Frank V., Tsao, Anne, Lam, Vincent K., Lu, Charles, Mott, Frank E., Simon, George, Antonoff, Mara B., Mehran, Reza J., Rice, David C., Behrens, Carmen, Weissferdt, Annikka, Moran, Cesar, Vaporciyan, Ara A., Lee, J. Jack, Swisher, Stephen G., Gibbons, Don L., Wistuba, Ignacio I., William, William N., Heymach, John V.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446232/
https://ncbi.nlm.nih.gov/pubmed/32193228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4180
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky